U.S. FDA Broadens Indication for Verzenioยฎ (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer | Eli Lilly and Company

The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.

Read the full article here

Related Articles

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer – Merck.com

KEYTRUDAยฎ (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with…